Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 95

1.

Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies.

Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L, Sheron N.

J Hepatol. 2018 May 16. pii: S0168-8278(18)32057-9. doi: 10.1016/j.jhep.2018.05.011. [Epub ahead of print] Review.

PMID:
29777749
2.

Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK.

Williams R, Alexander G, Armstrong I, Baker A, Bhala N, Camps-Walsh G, Cramp ME, de Lusignan S, Day N, Dhawan A, Dillon J, Drummond C, Dyson J, Foster G, Gilmore I, Hudson M, Kelly D, Langford A, McDougall N, Meier P, Moriarty K, Newsome P, O'Grady J, Pryke R, Rolfe L, Rice P, Rutter H, Sheron N, Taylor A, Thompson J, Thorburn D, Verne J, Wass J, Yeoman A.

Lancet. 2018 Mar 17;391(10125):1097-1107. doi: 10.1016/S0140-6736(17)32866-0. Epub 2017 Nov 29. Erratum in: Lancet. 2017 Dec 7;:.

PMID:
29198562
3.

Guidelines on the management of abnormal liver blood tests.

Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, Hall R, Harrower U, Hudson M, Langford A, Mackie A, Mitchell-Thain R, Sennett K, Sheron NC, Verne J, Walmsley M, Yeoman A.

Gut. 2018 Jan;67(1):6-19. doi: 10.1136/gutjnl-2017-314924. Epub 2017 Nov 9.

4.

Should we screen for cirrhosis?

Hudson M, Sheron N, Rowe IA, Hirschfield GM.

BMJ. 2017 Jul 12;358:j3233. doi: 10.1136/bmj.j3233. No abstract available.

PMID:
28701337
5.

Missed opportunities for intervention in alcohol-related liver disease in the UK.

Burton R, Sheron N.

Lancet Gastroenterol Hepatol. 2017 Jul;2(7):469-471. doi: 10.1016/S2468-1253(17)30082-1. No abstract available.

PMID:
28606872
6.

New metrics for the Lancet Standing Commission on Liver Disease in the UK.

Williams R, Alexander G, Aspinall R, Bosanquet J, Camps-Walsh G, Cramp M, Day N, Dhawan A, Dillon J, Dyson J, Ferguson J, Foster G, Gardner R, Gilmore SI, Hardman L, Hudson M, Kelly D, Langford A, Liversedge S, Moriarty K, Newsome P, O'Grady J, Pryke R, Rolfe L, Rutter H, Ryder S, Samyn M, Sheron N, Taylor A, Thompson J, Verne J, Yeoman A.

Lancet. 2017 May 20;389(10083):2053-2080. doi: 10.1016/S0140-6736(16)32234-6. Epub 2016 Dec 16. No abstract available.

PMID:
27989558
7.

A rapid evidence review of the effectiveness and cost-effectiveness of alcohol control policies: an English perspective.

Burton R, Henn C, Lavoie D, O'Connor R, Perkins C, Sweeney K, Greaves F, Ferguson B, Beynon C, Belloni A, Musto V, Marsden J, Sheron N.

Lancet. 2017 Apr 15;389(10078):1558-1580. doi: 10.1016/S0140-6736(16)32420-5. Epub 2016 Dec 2. Review.

8.

Effect of policy, economics, and the changing alcohol marketplace on alcohol related deaths in England and Wales.

Sheron N, Gilmore I.

BMJ. 2016 Apr 6;353:i1860. doi: 10.1136/bmj.i1860. No abstract available.

PMID:
27052417
9.

Exercise-Induced Systemic Venous Hypertension in the Fontan Circulation.

Navaratnam D, Fitzsimmons S, Grocott M, Rossiter HB, Emmanuel Y, Diller GP, Gordon-Walker T, Jack S, Sheron N, Pappachan J, Pratap JN, Vettukattil JJ, Veldtman G.

Am J Cardiol. 2016 May 15;117(10):1667-1671. doi: 10.1016/j.amjcard.2016.02.042. Epub 2016 Mar 3.

PMID:
27032711
10.

The alcohol harm paradox: using a national survey to explore how alcohol may disproportionately impact health in deprived individuals.

Bellis MA, Hughes K, Nicholls J, Sheron N, Gilmore I, Jones L.

BMC Public Health. 2016 Feb 18;16:111. doi: 10.1186/s12889-016-2766-x.

11.

Implementation of the Lancet Standing Commission on Liver Disease in the UK.

Williams R, Ashton K, Aspinall R, Bellis MA, Bosanquet J, Cramp ME, Day N, Dhawan A, Dillon J, Dyson J, Ferguson J, Foster G, Gilmore SI, Glynn M, Guthrie JA, Hudson M, Kelly D, Langford A, Newsome P, O'Grady J, Pryke R, Ryder S, Samyn M, Sheron N, Verne J.

Lancet. 2015 Nov 21;386(10008):2098-2111. doi: 10.1016/S0140-6736(15)00680-7. Epub 2015 Nov 20. No abstract available.

PMID:
26700394
12.

Alcohol and liver disease in Europe--Simple measures have the potential to prevent tens of thousands of premature deaths.

Sheron N.

J Hepatol. 2016 Apr;64(4):957-67. doi: 10.1016/j.jhep.2015.11.006. Epub 2015 Nov 16. Review.

PMID:
26592352
13.

Assessing feasibility and acceptability of a brief intervention for risky alcohol consumption in sexual health clinic attendees: a randomised controlled trial.

Roderick P, S Sundaram S, Dimitrov BD, Dewhirst S, Tucker LJ, Leydon G, Sheron N, Frater A, Harindra V.

J Fam Plann Reprod Health Care. 2016 Apr;42(2):143-51. doi: 10.1136/jfprhc-2014-100912. Epub 2015 Aug 10.

PMID:
26259896
14.

Evaluation of work-based screening for early signs of alcohol-related liver disease in hazardous and harmful drinkers: the PrevAIL study.

Cook PA, Morleo M, Billington D, Sanderson-Shortt K, Jones C, Gabbay M, Sheron N, Bellis MA, Phillips-Howard PA, Gilmore IT.

BMC Public Health. 2015 Jun 4;15:532. doi: 10.1186/s12889-015-1860-9.

15.

Alcoholic liver disease - the extent of the problem and what you can do about it.

Hazeldine S, Hydes T, Sheron N.

Clin Med (Lond). 2015 Apr;15(2):179-85. doi: 10.7861/clinmedicine.15-2-179. Review.

PMID:
25824072
16.

Commentary: Minimum unit price--how the evidence stacks up.

Sheron N, Eisenstein K.

BMJ. 2014 Jan 7;348:g67. doi: 10.1136/bmj.g67. No abstract available.

PMID:
25489933
17.

Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis.

Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, Ferguson J, Forton D, Foster G, Gilmore I, Hickman M, Hudson M, Kelly D, Langford A, Lombard M, Longworth L, Martin N, Moriarty K, Newsome P, O'Grady J, Pryke R, Rutter H, Ryder S, Sheron N, Smith T.

Lancet. 2014 Nov 29;384(9958):1953-97. Review. No abstract available. Erratum in: Lancet. 2014 Dec 20;384(9961):2212.

PMID:
25433429
18.

Impact of minimum price per unit of alcohol on patients with liver disease in the UK.

Sheron N, Chilcott F, Matthews L, Challoner B, Thomas M.

Clin Med (Lond). 2014 Aug;14(4):396-403. doi: 10.7861/clinmedicine.14-4-396.

PMID:
25099842
19.

Current treatment options for alcohol-related liver disease.

Hazeldine S, Sheron N.

Curr Opin Gastroenterol. 2014 May;30(3):238-44. doi: 10.1097/MOG.0000000000000065. Review.

PMID:
24662843
20.

Feasibility of detection and intervention for alcohol-related liver disease in the community: the Alcohol and Liver Disease Detection study (ALDDeS).

Sheron N, Moore M, O'Brien W, Harris S, Roderick P.

Br J Gen Pract. 2013 Oct;63(615):e698-705. doi: 10.3399/bjgp13X673711.

Supplemental Content

Loading ...
Support Center